Please assess the completion status of the following clinical trial:

Trial Title: Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic spontaneous urticaria (CSU) refractory to H1-antihistamine treatment~* Presence of itch an hives for more than 6 weeks~* UAS7 score of more than 14 (range 0-42)~* Patient has history of insufficient response to 4x of the approved dose of H1-antihistamines~* CSU diagnosis for more than 6 months~* Angioedema at least 4x in the last 6 months~Exclusion Criteria:~* Patients with non urticaria associated angioedema~* History of hypersensitivity to omalizumab or the rescue medication or to drugs of similar chemical structure~* Evidence of parasitic infection~* Previous treatment with omalizumab within the last 6 months prior to screening~* History of anaphylactic shock~* Woman who are pregnant or breast feeding~* Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 Omalizumab (Type: EXPERIMENTAL): omalizumab once a month via subcutaneous injection.
- 2 Placebo (Type: PLACEBO_COMPARATOR): placebo of omalizumab once a month via subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).